# Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)

> **NCT00280631** · PHASE1,PHASE2 · COMPLETED · sponsor: **Telik** · enrollment: 49 (actual)

## Conditions studied

- Myelodysplastic Syndrome (MDS)

## Interventions

- **DRUG:** Ezatiostat Hydrochlorine

## Key facts

- **NCT ID:** NCT00280631
- **Lead sponsor:** Telik
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-02
- **Primary completion:** 2008-03
- **Final completion:** 2008-06
- **Target enrollment:** 49 (ACTUAL)
- **Last updated:** 2012-05-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00280631

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00280631, "Study of TLK199 Tablets in Myelodysplastic Syndrome (MDS)". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00280631. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*